NDC 0338-0080 Doxorubicin Hydrochloride Liposome

Doxorubicin Hydrochloride Liposome

NDC Product Code 0338-0080

NDC Code: 0338-0080

Proprietary Name: Doxorubicin Hydrochloride Liposome What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Doxorubicin Hydrochloride Liposome What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

NDC Code Structure

  • 0338 - Baxter Healthcare Corporation
    • 0338-0080 - Doxorubicin Hydrochloride Liposome

NDC 0338-0080-01

Package Description: 1 VIAL, SINGLE-USE in 1 CARTON > 10 mL in 1 VIAL, SINGLE-USE

NDC Product Information

Doxorubicin Hydrochloride Liposome with NDC 0338-0080 is a a human prescription drug product labeled by Baxter Healthcare Corporation. The generic name of Doxorubicin Hydrochloride Liposome is doxorubicin hydrochloride liposome. The product's dosage form is injection, suspension, liposomal and is administered via intravenous form.

Labeler Name: Baxter Healthcare Corporation

Dosage Form: Injection, Suspension, Liposomal - A liquid preparation, suitable for injection, which consists of an oil phase dispersed throughout an aqueous phase in such a manner that liposomes (a lipid bilayer vesicle usually composed of phospholipids which is used to encapsulate an active drug substance, either within a lipid bilayer or in an aqueous space) are formed.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Doxorubicin Hydrochloride Liposome Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • DOXORUBICIN HYDROCHLORIDE 2 mg/mL

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE (UNII: 3L6NN8ZZKU)
  • CHOLESTEROL (UNII: 97C5T2UQ7J)
  • HYDROGENATED SOYBEAN LECITHIN (UNII: H1109Z9J4N)
  • AMMONIUM SULFATE (UNII: SU46BAM238)
  • HISTIDINE (UNII: 4QD397987E)
  • HYDROCHLORIC ACID (UNII: QTT17582CB)
  • SODIUM HYDROXIDE (UNII: 55X04QC32I)
  • SUCROSE (UNII: C151H8M554)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intravenous - Administration within or into a vein or veins.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Anthracycline Topoisomerase Inhibitor - [EPC] (Established Pharmacologic Class)
  • Anthracyclines - [CS]
  • Topoisomerase Inhibitors - [MoA] (Mechanism of Action)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Baxter Healthcare Corporation
Labeler Code: 0338
FDA Application Number: NDA050718 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: NDA - A product marketed under an approved New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 08-15-2019 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2020 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Information for Patients

Doxorubicin Lipid Complex Injection

Doxorubicin Lipid Complex Injection is pronounced as (dox oh roo' bi sin)

Why is doxorubicin lipid complex injection medication prescribed?
Doxorubicin lipid complex is used to treat ovarian cancer that has not improved or that has worsened after treatment with other medications. Doxorubicin lipid complex is ...
[Read More]

* Please review the disclaimer below.

Doxorubicin Hydrochloride Liposome Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

  • •Doxorubicin HCl liposome injection can cause myocardial damage, including congestive heart failure, as the total cumulative dose of doxorubicin HCl approaches 550 mg/m2. In a clinical study of 250 patients with advanced cancer who were treated with doxorubicin HCl liposome injection, the risk of cardiotoxicity was 11% when the cumulative anthracycline dose was between 450-550 mg/m2. Prior use of other anthracyclines or anthracenediones should be included in calculations of total cumulative dosage. The risk of cardiomyopathy may be increased at lower cumulative doses in patients with prior mediastinal irradiation [see Warnings and Precautions (5.1)]. •Acute infusion-related reactions consisting of, but not limited to, flushing, shortness of breath, facial swelling, headache, chills, back pain, tightness in the chest or throat, and/or hypotension occurred in 11% of patients with solid tumors treated with doxorubicin HCl liposome injection. Serious, life-threatening and fatal infusion reactions have been reported [see Dosage and Administration (2.6) and Warnings and Precautions (5.2)].

1.1 Ovarian Cancer

Doxorubicin HCl liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.

Doxorubicin HCl liposome injection is indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.

1.3 Multiple Myeloma

Doxorubicin HCl liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.

2.1 Important Use Information

Do not substitute doxorubicin HCl liposome injection for doxorubicin HCl injection.Do not administer as an undiluted suspension or as an intravenous bolus [see Warnings and Precautions (5.2)].

2.2 Ovarian Cancer

The recommended dose of doxorubicin HCl liposome injection is 50 mg/m2 intravenously over 60 minutes every 28 days until disease progression or unacceptable toxicity.

The recommended dose of doxorubicin HCl liposome injection is 20 mg/m2 intravenously over 60 minutes every 21 days until disease progression or unacceptable toxicity.

2.4 Multiple Myeloma

The recommended dose of doxorubicin HCl liposome injection is 30 mg/m2 intravenously over 60 minutes on day 4 of each 21-day cycle for eight cycles or until disease progression or unacceptable toxicity. Administer doxorubicin HCl liposome injection after bortezomib on day 4 of each cycle [see Clinical Studies (14.3)].

2.5 Dose Modifications For Adverse Reactions

  • Do not increase doxorubicin HCl liposome injection after a dose reduction for toxicity.Table 1: Recommended Dose Modifications for Hand-Foot Syndrome, Stomatitis, or Hematologic Adverse ReactionsToxicityDose AdjustmentHand-Foot Syndrome (HFS)Grade 1: Mild erythema, swelling, or desquamation not interfering with daily activities •If no previous Grade 3 or 4 HFS: no dose adjustment. •If previous Grade 3 or 4 HFS: delay dose up to 2 weeks, then decrease dose by 25%.Grade 2: Erythema, desquamation, or swelling interfering with, but not precluding normal physical activities; small blisters or ulcerations less than 2 cm in diameter •Delay dosing up to 2 weeks or until resolved to Grade 0-1. •Discontinue doxorubicin HCl liposome injection if no resolution after 2 weeks. •If resolved to Grade 0-1 within 2 weeks:oAnd no previous Grade 3 or 4 HFS: continue treatment at previous dose.oAnd previous Grade 3 or 4 toxicity: decrease dose by 25%.Grade 3: Blistering, ulceration, or swelling interfering with walking or normal daily activities; cannot wear regular clothing •Delay dosing up to 2 weeks or until resolved to Grade 0-1, then decrease dose by 25%. •Discontinue doxorubicin HCl liposome injection if no resolution after 2 weeks.Grade 4: Diffuse or local process causing infectious complications, or a bed ridden state or hospitalization •Delay dosing up to 2 weeks or until resolved to Grade 0-1, then decrease dose by 25%. •Discontinue doxorubicin HCl liposome injection if no resolution after 2 weeks.StomatitisGrade 1: Painless ulcers, erythema, or mild soreness •If no previous Grade 3 or 4 toxicity: no dose adjustment. •If previous Grade 3 or 4 toxicity: delay up to 2 weeks then decrease dose by 25%.Grade 2: Painful erythema, edema, or ulcers, but can eat •Delay dosing up to 2 weeks or until resolved to Grade 0-1. •Discontinue doxorubicin HCl liposome injection if there is no resolution after 2 weeks. •If resolved to Grade 0-1 within 2 weeks: oAnd no previous Grade 3 or 4 stomatitis: resume treatment at previous dose.oAnd previous Grade 3 or 4 toxicity: decrease dose by 25%.Grade 3: Painful erythema, edema, or ulcers, and cannot eat •Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to original dose interval. •If after 2 weeks there is no resolution, discontinue doxorubicin HCl liposome injection.Grade 4: Requires parenteral or enteral support •Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to original dose interval. •If after 2 weeks there is no resolution, discontinue doxorubicin HCl liposome injection.Neutropenia or ThrombocytopeniaGrade 1No dose reductionGrade 2Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume treatment at previous doseGrade 3Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume treatment at previous doseGrade 4Delay until ANC ≥ 1,500 and platelets ≥ 75,000; resume at 25% dose reduction or continue previous dose with prophylactic granulocyte growth factorTable 2: Recommended Dose Modifications of Doxorubicin HCl Liposome Injection for Toxicity When Administered in Combination With BortezomibToxicityDoxorubicin HCl liposome injection Fever ≥38°C and ANC <1,000/mm3 •Withhold dose for this cycle if before Day 4; •Decrease dose by 25%, if after Day 4 of previous cycle.On any day of drug administration after Day 1 of each cycle: •Platelet count <25,000/mm3 •Hemoglobin <8 g/dL •ANC <500/mm3 •Withhold dose for this cycle if before Day 4; •Decrease dose by 25%, if after Day 4 of previous cycle AND if bortezomib is reduced for hematologic toxicity.Grade 3 or 4 non-hematologic drug related toxicityDo not dose until recovered to Grade <2, then reduce dose by 25%.For neuropathic pain or peripheral neuropathy, no dosage adjustments are required for doxorubicin HCl liposome injection. Refer to bortezomib manufacturer’s prescribing information.

2.6 Preparation And Administration

  • PreparationDilute doxorubicin HCl liposome injection doses up to 90 mg in 250 mL of 5% Dextrose Injection, USP prior to administration. Dilute doses exceeding 90 mg in 500 mL of 5% Dextrose Injection, USP prior to administration. Refrigerate diluted doxorubicin HCl liposome injection at 2°C to 8°C (36°F to 46°F) and administer within 24 hours.AdministrationInspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if a precipitate or foreign matter is present.Do not use with in-line filters.Administer the first dose of doxorubicin HCl liposome injection at an initial rate of 1 mg/min. If no infusion-related adverse reactions are observed, increase the infusion rate to complete the administration of the drug over one hour [see Warnings and Precautions (5.2)]. Do not rapidly flush the infusion line. Do not mix doxorubicin HCl liposome injection with other drugs.Management of Suspected ExtravasationDiscontinue doxorubicin HCl liposome injection for burning or stinging sensation or other evidence indicating perivenous infiltration or extravasation. Manage confirmed or suspected extravasation as follows: •Do not remove the needle until attempts are made to aspirate extravasated fluid •Do not flush the line •Avoid applying pressure to the site •Apply ice to the site intermittently for 15 min 4 times a day for 3 days •If the extravasation is in an extremity, elevate the extremity

2.7 Procedure For Proper Handling And Disposal

Doxorubicin HCl liposome injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 If doxorubicin HCl liposome injection comes into contact with skin or mucosa, immediately wash thoroughly with soap and water.

3 Dosage Forms And Strengths

Doxorubicin HCl liposomal injection: single-dose vials contain 20 mg/10 mL and 50 mg/25 mL doxorubicin HCl as a translucent, red liposomal dispersion.

4 Contraindications

Doxorubicin HCl liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin HCl [see Warnings and Precautions (5.2)].

5.1 Cardiomyopathy

Doxorubicin HCl can result in myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy with doxorubicin HCl is generally proportional to the cumulative exposure. The relationship between cumulative doxorubicin HCl liposome injection dose and the risk of cardiac toxicity has not been determined.In a clinical study in 250 patients with advanced cancer who were treated with doxorubicin HCl liposome injection, the risk of cardiotoxicity was 11% when the cumulative anthracycline dose was between 450‑550 mg/m2. Cardiotoxicity was defined as >20% decrease in resting left ventricular ejection fraction (LVEF) from baseline where LVEF remained in the normal range or a >10% decrease in LVEF from baseline where LVEF was less than the institutional lower limit of normal. Two percent of patients developed signs and symptoms of congestive heart failure without documented evidence of cardiotoxicity.Assess left ventricular cardiac function (e.g. MUGA or echocardiogram) prior to initiation of doxorubicin HCl liposome injection, during treatment to detect acute changes, and after treatment to detect delayed cardiotoxicity. Administer doxorubicin HCl liposome injection to patients with a history of cardiovascular disease only when the potential benefit of treatment outweighs the risk.

Serious and sometimes life-threatening infusion-related reactions characterized by one or more of the following symptoms can occur with doxorubicin HCl liposome injection: flushing, shortness of breath, facial swelling, headache, chills, chest pain, back pain, tightness in the chest and throat, fever, tachycardia, pruritus, rash, cyanosis, syncope, bronchospasm, asthma, apnea, and hypotension. The majority of infusion-related events occurred during the first infusion. Of 239 patients with ovarian cancer treated with doxorubicin HCl liposome injection in Trial 4, 7% of patients experienced acute infusion-related reactions resulting in dose interruption. All occurred during cycle 1 and none during subsequent cycles. Across multiple studies of doxorubicin HCl liposome injection monotherapy including this and other studies enrolling 760 patients with various solid tumors, 11% of patients had infusion-related reactions.Ensure that medications to treat infusion-related reactions and cardiopulmonary resuscitative equipment are available for immediate use prior to initiation of doxorubicin HCl liposome injection. Initiate doxorubicin HCl liposome injection infusions at a rate of 1 mg/min and increase rate as tolerated [see Dosage and Administration (2.6)]. In the event of an infusion-related reaction, temporarily stop the drug until resolution then resume at a reduced infusion rate. Discontinue doxorubicin HCl liposome injection infusion for serious or life-threatening infusion-related reactions.

5.3 Hand-Foot Syndrome (Hfs)

In Trial 4, the incidence of HFS was 51% of patients in the doxorubicin HCl liposome injection arm and 0.9% of patients in the topotecan arm, including 24% Grade 3 or 4 cases of HFS in doxorubicin HCl liposome injection-treated patients and no Grade 3 or 4 cases in topotecan-treated patients. HFS or other skin toxicity required discontinuation of doxorubicin HCl liposome injection in 4.2% of patients.HFS was generally observed after 2 or 3 cycles of treatment but may occur earlier. Delay doxorubicin HCl liposome injection for the first episode of Grade 2 or greater HFS [see Dosage and Administration (2.5)]. Discontinue doxorubicin HCl liposome injection if HFS is severe and debilitating.

5.4 Secondary Oral Neoplasms

Secondary oral cancers, primarily squamous cell carcinoma, have been reported from post‑marketing experience in patients with long-term (more than one year) exposure to doxorubicin HCl liposome injection. These malignancies were diagnosed both during treatment with doxorubicin HCl liposome injection and up to 6 years after the last dose. Examine patients at regular intervals for the presence of oral ulceration or with any oral discomfort that may be indicative of secondary oral cancer.The altered pharmacokinetics and preferential tissue distribution of liposomal doxorubicin that contributes to enhanced skin toxicity and mucositis compared to free doxorubicin may play a role in the development of oral secondary malignancies with long-term use.

5.5 Embryofetal Toxicity

Based on animal data, doxorubicin HCl liposome injection can cause fetal harm when administered to a pregnant woman. At doses approximately 0.12 times the recommended clinical dose, doxorubicin HCl liposome injection was embryotoxic and abortifacient in rabbits. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during and for 6 months after treatment with doxorubicin HCl liposome injection [see Use in Specific Populations (8.1) and (8.3)].

6 Adverse Reactions

  • The following adverse reactions are discussed in more detail in other sections of the labeling. •Cardiomyopathy [see Warnings and Precautions (5.1)] •Infusion-Related Reactions [see Warnings and Precautions (5.2)] •Hand-Foot Syndrome [see Warnings and Precautions (5.3)] •Secondary Oral Neoplasms [see Warnings and Precautions (5.4)]The most common adverse reactions (>20%) observed with doxorubicin HCl liposome injection are asthenia, fatigue, fever, nausea, stomatitis, vomiting, diarrhea, constipation, anorexia, hand-foot syndrome, rash and neutropenia, thrombocytopenia and anemia.

6.1 Adverse Reactions In Clinical Trials

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates on other clinical trials and may not reflect the rates observed in clinical practice.The safety data reflect exposure to doxorubicin HCl liposome injection in 1310 patients including: 239 patients with ovarian cancer, 753 patients with AIDS-related Kaposi’s sarcoma, and 318 patients with multiple myeloma.The following tables present adverse reactions from clinical trials of single-agent doxorubicin HCl liposome injection in ovarian cancer and AIDS-Related Kaposi’s sarcoma.Patients With Ovarian CancerThe safety data described below are from Trial 4, which included 239 patients with ovarian cancer treated with doxorubicin HCl liposome injection 50 mg/m2 once every 4 weeks for a minimum of four courses in a randomized, multicenter, open-label study. In this trial, patients received doxorubicin HCl liposome injection for a median number of 3.2 months (range 1 day to 25.8 months). The median age of the patients is 60 years (range 27 to 87), with 91% Caucasian, 6% Black, and 3% Hispanic or Other.Table 3 presents the hematologic adverse reactions from Trial 4.Table 3: Hematologic Adverse Reactions in Trial 4Doxorubicin HCl Liposome Injection Patients(n=239)TopotecanPatients(n=235)Neutropenia500 - <1000/mm38%14%<500/mm34.2%62%Anemia6.5 - <8 g/dL5%25%< 6.5 g/dL0.4%4.3%Thrombocytopenia10,000 - <50,000/mm31.3%17%<10,000/mm30.0%17%Table 4 presents the non-hematologic adverse reactions from Trial 4.Table 4: Non-Hematologic Adverse Reactions in Trial 4Non-HematologicAdverse Reaction10% or GreaterDoxorubicin HCl Liposome Injection (%)treated(n=239)Topotecan (%)treated(n=235)All gradesGrades 3-4All gradesGrades 3-4DigestiveNausea465638Stomatitis418150.4Vomiting3384410Diarrhea212.5354.2Anorexia202.5221.3Dyspepsia120.8140NervousDizziness4.20100RespiratoryPharyngitis160180.4Dyspnea154.1234.3Cough increased100120Skin and AppendagesHand-foot syndrome51240.90Rash294.2120.4Alopecia19N/A52N/AThe following additional adverse reactions were observed in patients with ovarian cancer with doses administered every four weeks (Trial 4).Incidence 1% to 10%Cardiovascular: vasodilation, tachycardia, deep vein thrombosis, hypotension, cardiac arrest.Digestive: oral moniliasis, mouth ulceration, esophagitis, dysphagia, rectal bleeding, ileus.Hematologic and Lymphatic: ecchymosis.Metabolic and Nutritional: dehydration, weight loss, hyperbilirubinemia, hypokalemia, hypercalcemia, hyponatremia.Nervous: somnolence, dizziness, depression.Respiratory: rhinitis, pneumonia, sinusitis, epistaxis.Skin and Appendages: pruritus, skin discoloration, vesiculobullous rash, maculopapular rash, exfoliative dermatitis, herpes zoster, dry skin, herpes simplex, fungal dermatitis, furunculosis, acne.Special Senses: conjunctivitis, taste perversion, dry eyes.Urinary: urinary tract infection, hematuria, vaginal moniliasis.Patients With AIDS-Related Kaposi’s SarcomaThe safety data described is based on the experience reported in 753 patients with AIDS‑related Kaposi’s sarcoma (KS) enrolled in four open-label, uncontrolled trials of doxorubicin HCl liposome injection administered at doses ranging from 10 to 40 mg/m2 every 2 to 3 weeks. Demographics of the population were: median age 38.7 years (range 24-70); 99% male; 88% Caucasian, 6% Hispanic, 4% Black, and 2% Asian/other/unknown. The majority of patients were treated with 20 mg/m2 of doxorubicin HCl liposome injection every 2 to 3 weeks with a median exposure of 4.2 months (range 1 day to 26.6 months). The median cumulative dose was 120 mg/m2 (range 3.3 to 798.6 mg/m2); 3% received cumulative doses of greater than 450 mg/m2.Disease characteristics were: 61% poor risk for KS tumor burden, 91% poor risk for immune system, and 47% poor risk for systemic illness; 36% were poor risk for all three categories; median CD4 count 21 cells/mm3 (51% less than 50 cells/mm3); mean absolute neutrophil count at study entry approximately 3,000 cells/mm3.Of the 693 patients with concomitant medication information, 59% were on one or more antiretroviral medications [35% zidovudine (AZT), 21% didanosine (ddI), 16% zalcitabine (ddC), and 10% stavudine (D4T)]; 85% received PCP prophylaxis (54% sulfamethoxazole/trimethoprim); 85% received antifungal medications (76% fluconazole); 72% received antivirals (56% acyclovir, 29% ganciclovir, and 16% foscarnet) and 48% patients received colony-stimulating factors (sargramostim/filgrastim) during their course of treatment.Adverse reactions led to discontinuation of treatment in 5% of patients with AIDS‑related Kaposi’s sarcoma and included myelosuppression, cardiac adverse reactions, infusion‑related reactions, toxoplasmosis, HFS, pneumonia, cough/dyspnea, fatigue, optic neuritis, progression of a non-KS tumor, allergy to penicillin, and unspecified reasons. Tables 5 and 6 summarize adverse reactions reported in patients treated with doxorubicin HCl liposome injection for AIDS-related Kaposi’s sarcoma in a pooled analysis of the four trials.Table 5: Hematologic Adverse Reactions Reported in Patients With AIDS-Related Kaposi’s SarcomaPatients With Refractory or Intolerant AIDS-Related Kaposi’s Sarcoma(n=74*)Total Patients With AIDS-RelatedKaposi’s Sarcoma(n=720**)Neutropenia< 1000/mm346%49%< 500/mm311%13%Anemia< 10 g/dL58%55%< 8 g/dL16%18%Thrombocytopenia< 150,000/mm361%61%< 25,000/mm31.4%4.2%*This includes a subset of subjects who were retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least 2 cycles of a regimen containing at least 2 of 3 treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy.**This includes only subjects with AIDS-KS who had available data from the 4 pooled trials.Table 6: Non-Hematologic Adverse Reactions Reported in ≥ 5% of Patients With AIDS-Related Kaposi’s SarcomaAdverse ReactionsPatients With Refractory or Intolerant AIDS-Related Kaposi’s Sarcoma(n=77*)Total Patients With AIDS - RelatedKaposi’s Sarcoma(n=705**)Nausea18%17%Asthenia7%10%Fever8%9%Alopecia9%9%Alkaline Phosphatase Increase1.3%8%Vomiting8%8%Diarrhea5%8%Stomatitis5%7%Oral Moniliasis1.3%6%*This includes a subset of subjects who were retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least 2 cycles of a regimen containing at least 2 of 3 treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy.**This includes only subjects with AIDS-KS who had available adverse event data from the 4 pooled trials.The following additional adverse reactions were observed in 705 patients with AIDS-related Kaposi’s sarcoma.Incidence 1% to 5%Body as a Whole: headache, back pain, infection, allergic reaction, chills.Cardiovascular: chest pain, hypotension, tachycardia.Cutaneous: herpes simplex, rash, itching.Digestive: mouth ulceration, anorexia, dysphagia.Metabolic and Nutritional: SGPT increase, weight loss, hyperbilirubinemia.Other: dyspnea, pneumonia, dizziness, somnolence.Incidence Less Than 1%Body As A Whole: sepsis, moniliasis, cryptococcosis.Cardiovascular: thrombophlebitis, cardiomyopathy, palpitation, bundle branch block, congestive heart failure, heart arrest, thrombosis, ventricular arrhythmia.Digestive: hepatitis.Metabolic and Nutritional Disorders: dehydration.Respiratory: cough increase, pharyngitis.Skin and Appendages: maculopapular rash, herpes zoster.Special Senses: taste perversion, conjunctivitis.Patients With Multiple MyelomaThe safety data described are from 318 patients treated with doxorubicin HCl liposome injection (30 mg/m2) administered on day 4 following bortezomib (1.3 mg/m2 i.v. bolus on days 1, 4, 8 and 11) every 3 weeks, in a randomized, open-label, multicenter study (Trial 6). In this trial, patients in the doxorubicin HCl liposome injection+ bortezomib combination group were treated for a median number of 4.5 months (range 21 days to 13.5 months). The population was 28 to 85 years of age (median age 61), 58% male, 90% Caucasian, 6% Black, and 4% Asian and Other. Table 7 lists adverse reactions reported in 10% or more of patients treated with doxorubicin HCl liposome injection in combination with bortezomib for multiple myeloma.Table 7: Frequency of Treatment-Emergent Adverse Reactions Reported in ≥10% Patients Treated for Multiple Myeloma With Doxorubicin HCl Liposome Injection in Combination With BortezomibAdverse ReactionDoxorubicin HCl liposome injection + bortezomib(n=318)Bortezomib(n=318)Any (%)Grade 3-4Any (%)Grade 3-4Blood and lymphatic system disordersNeutropenia36322216Thrombocytopenia33242817Anemia259219General disorders and administration site conditionsFatigue367283Pyrexia311221Asthenia226184Gastrointestinal disordersNausea483401Diarrhea467395Vomiting324221Constipation311311Mucositis/Stomatitis2025<1Abdominal pain11181Infections and infestationsHerpes zoster11292Herpes simplex10061InvestigationsWeight decreased12040Metabolism and Nutritional disordersAnorexia19214<1Nervous system disordersPeripheral Neuropathy14274511Neuralgia173204Paresthesia/dysesthesia13<1100Respiratory, thoracic and mediastinal disordersCough180120Skin and subcutaneous tissue disordersRash2221181Hand-foot syndrome196<101Peripheral neuropathy includes the following adverse reactions: peripheral sensory neuropathy, neuropathy peripheral, polyneuropathy, peripheral motor neuropathy, and neuropathy NOS.2Rash includes the following adverse reactions: rash, rash erythematous, rash macular, rash maculo-papular, rash pruritic, exfoliative rash, and rash generalized.

6.2 Postmarketing Experience

The following additional adverse reactions have been identified during post approval use of doxorubicin HCl liposome injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.Musculoskeletal and Connective Tissue Disorders: muscle spasmsRespiratory, Thoracic and Mediastinal Disorders: pulmonary embolism (in some cases fatal)Hematologic disorders: Secondary acute myelogenous leukemiaSkin and subcutaneous tissue disorders: erythema multiforme, Stevens‑Johnson syndrome, toxic epidermal necrolysisSecondary oral neoplasms: [see Warnings and Precautions (5.4)].

7 Drug Interactions

No formal drug interaction studies have been conducted with doxorubicin HCl liposome injection.

8.1 Pregnancy

Risk SummaryBased on findings in animals, doxorubicin HCl liposome injection can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, doxorubicin HCl liposome injection was embryotoxic in rats and abortifacient in rabbits following intravenous administration during organogenesis at doses approximately 0.12 times the recommended clinical dose [see Data]. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus.The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.DataAnimal DataDoxorubicin HCl liposome injection was embryotoxic at doses of 1 mg/kg/day in rats and was embryotoxic and abortifacient at 0.5 mg/kg/day in rabbits (both doses are about 0.12 times the recommended dose of 50 mg/m2 human dose on a mg/m2 basis). Embryotoxicity was characterized by increased embryo-fetal deaths and reduced live litter sizes.

8.2 Lactation

Risk SummaryIt is not known whether doxorubicin HCl liposome injection is present in human milk. Because many drugs, including anthracyclines, are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from doxorubicin HCl liposome injection, discontinue breastfeeding during treatment with doxorubicin HCl liposome injection.

8.3 Females And Males Of Reproductive Potential

ContraceptionFemalesDoxorubicin HCl liposome injection can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during and for 6 months after treatment with doxorubicin HCl liposome injection.MalesDoxorubicin HCl liposome injection may damage spermatozoa and testicular tissue, resulting in possible genetic fetal abnormalities. Males with female sexual partners of reproductive potential should use effective contraception during and for 6 months after treatment with doxorubicin HCl liposome injection [see Non‑clinical Toxicology (13.1)].InfertilityFemalesIn females of reproductive potential, doxorubicin HCl liposome injection may cause infertility and result in amenorrhea. Premature menopause can occur with doxorubicin HCl. Recovery of menses and ovulation is related to age at treatment.MalesDoxorubicin HCl liposome injection may result in oligospermia, azoospermia, and permanent loss of fertility. Sperm counts have been reported to return to normal levels in some men. This may occur several years after the end of therapy [see Non-clinical Toxicology (13.1)].

8.4 Pediatric Use

The safety and effectiveness of doxorubicin HCl liposome injection in pediatric patients have not been established.

8.5 Geriatric Use

Clinical studies of doxorubicin HCl liposome injection conducted in patients with either epithelial ovarian cancer (Trial 4) or with AIDS-related Kaposi’s sarcoma (Trial 5) did not contain sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger subjects.In Trial 6, of 318 patients treated with doxorubicin HCl liposome injection in combination with bortezomib for multiple myeloma, 37% were 65 years of age or older and 8% were 75 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients.

8.6 Hepatic Impairment

The pharmacokinetics of doxorubicin HCl liposome injection has not been adequately evaluated in patients with hepatic impairment. Doxorubicin is eliminated in large part by the liver. Reduce doxorubicin HCl liposome injection for serum bilirubin of 1.2 mg/dL or higher.

10 Overdosage

Acute overdosage with doxorubicin HCl causes increased risk of severe mucositis, leukopenia, and thrombocytopenia.

11 Description

Doxorubicin HCl liposome injection is doxorubicin hydrochloride (HCl), an anthracycline topoisomerase II inhibitor, that is encapsulated in STEALTH liposomes for intravenous use.The chemical name of doxorubicin HCl is (8S,10S)-10-[(3-amino-2,3,6‑trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-glycolyl-7,8,9,10-tetrahydro-6,8,11‑trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride. The molecular formula is C27-H29 -NO11•HCl; its molecular weight is 579.99.The molecular structure is:Doxorubicin HCl liposome injection is a sterile, translucent, red liposomal dispersion in 10‑mL or 30-mL glass, single-dose vials. Each vial contains 20 mg or 50 mg doxorubicin HCl at a concentration of 2 mg/mL and a pH of 6.5. The STEALTH liposome carriers are composed of cholesterol, 3.19 mg/mL; fully hydrogenated soy phosphatidylcholine (HSPC), 9.58 mg/mL; and N‑(carbonyl‑methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3‑phosphoethanolamine sodium salt (MPEG-DSPE), 3.19 mg/mL. Each mL also contains ammonium sulfate, approximately 0.6 mg; histidine as a buffer; hydrochloric acid and/or sodium hydroxide for pH control; and sucrose to maintain isotonicity. Greater than 90% of the drug is encapsulated in the STEALTH liposomes.MPEG-DSPE has the following structural formula:HSPC has the following structural formula:Representation of a STEALTH liposome:

12.1 Mechanism Of Action

The active ingredient of doxorubicin HCl liposome injection is doxorubicin HCl. The mechanism of action of doxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and induction of mutagenesis and chromosomal aberrations.

12.3 Pharmacokinetics

The pharmacokinetic parameters for total doxorubicin following a single dose of doxorubicin HCl liposome injection infused over 30 minutes are presented in Table 8.Table 8: Pharmacokinetic Parameters of Total Doxorubicin from Doxorubicin HCl Liposome Injection in Patients With AIDS-Related Kaposi’s SarcomaDoseParameter (units)10 mg/m220 mg/m2Peak Plasma Concentration (μg/mL)4.12 ± 0.2158.34 ± 0.49Plasma Clearance (L/h/m2)0.056 ± 0.010.041 ± 0.004Steady State Volume of Distribution (L/m2)2.83 ± 0.1452.72 ± 0.120AUC (μg/mL•h)277 ± 32.9590 ± 58.7First Phase (λ1) Half-Life (h)4.7 ± 1.15.2 ± 1.4Second Phase (λ1) Half-Life (h)52.3 ± 5.655.0 ± 4.8N=23Mean ± Standard ErrorDoxorubicin HCl liposome injection displayed linear pharmacokinetics over the range of 10 to 20 mg/m2. Relative to doxorubicin HCl liposome injection doses at or below 20 mg/m2, the pharmacokinetics of total doxorubicin following a 50 mg/m2 doxorubicin HCl liposome injection dose are nonlinear. At this dose, the elimination half-life of doxorubicin HCl liposome injection is longer and the clearance lower compared to a 20 mg/m2 dose.Distribution:Direct measurement of liposomal doxorubicin shows that at least 90% of the drug (the assay used cannot quantify less than 5-10% free doxorubicin) remains liposome‑encapsulated during circulation.In contrast to doxorubicin, which displays a large volume of distribution (range 700 to 1100 L/m2), the small steady state volume of distribution of liposomal doxorubicin suggests that doxorubicin HCl liposome injection is largely confined to vascular fluid. Doxorubicin becomes available after the liposomes are extravasated. Plasma protein binding of doxorubicin HCl liposome injection has not been determined; the plasma protein binding of doxorubicin is approximately 70%.Metabolism:Doxorubicinol, the major metabolite of doxorubicin, was detected at concentrations of 0.8 to 26.2 ng/mL in the plasma of patients who received 10 or 20 mg/m2 doxorubicin HCl liposome injection.Elimination:The plasma clearance of total doxorubicin from doxorubicin HCl liposome injection was 0.041 L/h/m2 at a dose of 20 mg/m2. Following administration of doxorubicin HCl, the plasma clearance of doxorubicin is 24 to 35 L/h/m2.

13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

Mutagenicity or carcinogenicity studies have not been conducted with doxorubicin HCl liposome injection, however doxorubicin was shown to be mutagenic in the in vitro Ames assay, and clastogenic in multiple in vitro assays (CHO cell, V79 hamster cell, human lymphoblast, and SCE assays) and the in vivo mouse micronucleus assay. The possible adverse effects on fertility in animals have not been adequately evaluated. Doxorubicin HCl liposome injection resulted in mild to moderate ovarian and testicular atrophy in mice after administration of a single dose of 36 mg/kg (about 2 times the 50 mg/m2 human dose on a mg/m2 basis). Decreased testicular weights and hypospermia were observed in rats after repeat doses ≥ 0.25 mg/kg/day (about 0.03 times the 50 mg/m2 human dose on a mg/m2 basis), and diffuse degeneration of the seminiferous tubules and a marked decrease in spermatogenesis were observed in dogs after repeat doses of 1 mg/kg/day (about 0.4 times the 50 mg/m2 human dose on a mg/m2 basis).

14.1 Ovarian Cancer

Doxorubicin HCl liposome injection was studied in three open-label, single-arm, clinical studies of 176 patients with metastatic ovarian cancer (Trials 1, 2, and 3). One hundred forty‑five of these patients were refractory to both paclitaxel- and platinum-based chemotherapy regimens, defined as disease progression while on treatment or relapse within 6 months of completing treatment. Patients received doxorubicin HCl liposome injection at 50 mg/m2 every 3 or 4 weeks for 3-6+ cycles in the absence of dose‑limiting toxicity or disease progression.The median age at diagnosis ranged from 52 to 64 years in the 3 studies, and the range was 22 to 85. Most patients had International Federation of Obstetricians and Gynecologists (FIGO) stage III or IV disease (ranging from 83% to 93%). Approximately one third of the patients had three or more prior lines of therapy (ranging from 22% to 33%).The primary outcome measure was confirmed response rate based on Southwestern Oncology Group (SWOG) criteria for patients refractory to both paclitaxel- and a platinum‑containing regimen. Secondary efficacy parameters were time to response, duration of response, and time to progression.The response rates for the individual single arm trials are given in Table 9 below.Table 9: Response Rates in Patients With Refractory Ovarian Cancer From Single Arm Ovarian Cancer TrialsTrial 1 (U.S.)N=27Trial 2 (U.S.)N=82Trial 3 (non-U.S.)N=36Response Rate22.2%17.1%0%95% Confidence Interval8.6% ‑ 42.3%9.7% ‑ 27.0%0.0% ‑ 9.7%In a pooled analysis of Trials 1-3, the response rate for all patients refractory to paclitaxel and platinum agents was 13.8% (95% CI 8.1% to 19.3%). The median time to progression was 15.9 weeks, the median time to response was 17.6 weeks, and the duration of response was 39.4 weeks.In Trial 4, a randomized, multicenter, open-label, trial in 474 patients with epithelial ovarian cancer after platinum-based chemotherapy, patients were randomized to receive either doxorubicin HCl liposome injection 50 mg/m2 every 4 weeks (n=239) or topotecan 1.5 mg/m2 daily for 5 consecutive days every 3 weeks (n=235). Patients were stratified according to platinum sensitivity (response to initial platinum-based therapy and a progression-free interval of greater than 6 months off treatment) and the presence of bulky disease (tumor mass greater than 5 cm in size). The primary outcome measure was time to progression (TTP). Other endpoints included overall survival and objective response rate.Of the 474 patients, the median age at diagnosis was 60 years (range 25 to 87), 90% were FIGO stage III and IV; 46% were platinum sensitive; and 45% had bulky disease.There was no statistically significant difference in TTP between the two arms. Results are provided in Table 10.Table 10: Results of Efficacy Analyses1Protocol Defined ITT PopulationDoxorubicin HCl Liposome Injection(n=239)Topotecan(n=235)TTP (Protocol Specified Primary Endpoint)Median (Months)24.14.2p-value30.62Hazard Ratio4 95% CI for Hazard Ratio0.96(0.76, 1.20)Overall SurvivalMedian (Months) 214.413.7p-value5 Hazard Ratio40.050.8295% CI for Hazard Ratio(0.68, 1.00)Response RateOverall Response n (%)47 (19.7)40 (17.0)Complete Response n (%)9 (3.8)11 (4.7)Partial Response n (%)38 (15.9)29 (12.3)Median Duration of Response (Months) 26.95.91Analysis based on investigators’ strata for protocol defined ITT population.2Kaplan-Meier estimates.3p-value is based on the stratified log-rank test.4Hazard ratio is based on Cox proportional-hazard model with the treatment as single independent variable. A hazard ratio less than 1 indicates an advantage for doxorubicin HCl liposome injection.5p-value not adjusted for multiple comparisons.

Doxorubicin HCl liposome injection was studied in an open-label, single-arm, multicenter study at a dose of 20 mg/m2 every 3 weeks, until disease progression or unacceptable toxicity (Trial 5).Data is described for a cohort of 77 patients retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least two cycles of a regimen containing at least two of three treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy. Forty-nine of the 77 (64%) patients had received prior doxorubicin HCl.The median time on study was 5.1 months (range 1 day to 15 months). The median cumulative dose of doxorubicin HCl liposome injection was 154 mg/m2 (range 20 to 620 mg/m2). Among the 77 patients, mean age was 38 years (range 24 to 54); 87% were Caucasian, 5% Hispanic, 4% Black, and 4% Asian/Other/Unknown; median CD4 count was 10 cells/mm3; ACTG staging criteria were 78% poor risk for tumor burden, 96% poor risk for immune system, and 58% poor risk for systemic illness at baseline; and mean Karnofsky status score was 74%. All patients had cutaneous or subcutaneous lesions, 40% also had oral lesions, 26% pulmonary lesions, and 14% had lesions of the stomach/intestine.Two analyses of tumor response were used: one based on investigator assessment of changes in lesions based on modified ACTG criteria (partial response defined as no new lesions, sites of disease, or worsening edema; flattening of ≥50% of previously raised lesions or area of indicator lesions decreasing by ≥50%; and response lasting at least 21 days with no prior progression), and one based on changes in up to five prospectively indentified representative indicator lesions (partial response defined as flattening of ≥50% of previously raised indicator lesions, or >50% decrease in the area of indicator lesions and lasting at least 21 days with no prior progression).Of the 77 patients, 34 were evaluable for investigator assessment and 42 were evaluable for indicator lesion assessment; analyses of tumor responses are shown in Table 11.Table 11: Response in Patients with Refractory1 AIDS-Related Kaposi’s SarcomaInvestigator AssessmentAll EvaluablePatients(n=34)Evaluable PatientsWho Received PriorDoxorubicin(n=20)Response2Partial (PR)27%30%Stable29%40%Progression44%30%Duration of PR (Days)Median7389Range42+ - 210+42+ - 210+Time to PR (Days)Median4353Range15 – 13315 - 109Indicator Lesion AssessmentAll EvaluablePatients(n=42)Evaluable PatientsWho Received PriorDoxorubicin(n=23)Response2Partial (PR)48%52%Stable26%30%Progression26%17%Duration of PR (Days)Median7179Range22+ - 210+35 – 210+Time to PR (Days)Median2248Range15 – 10915 – 1091Patients with disease that progressed on prior combination chemotherapy or who were intolerant to such therapy.2There were no complete responses in this population.Retrospective efficacy analyses were performed in two trials that had subsets of patients who received single-agent doxorubicin HCl liposome injection and who were on stable antiretroviral therapy for at least 60 days prior to enrollment and until a response was demonstrated. In one trial, 7 of 17 (40%) patients had a durable response (median duration not reached but was longer than 11.6 months). In the second trial, 4 of 11 patients (40%) on a stable antiretroviral therapy demonstrated durable responses.

14.3 Multiple Myeloma

The efficacy of doxorubicin HCl liposome injection in combination with bortezomib was evaluated in Trial 6, a randomized, open-label, international, multicenter study in 646 patients who had not previously received bortezomib and whose disease progressed during or after at least one prior therapy. Patients were randomized (1:1) to receive either doxorubicin HCl liposome injection (30 mg/m2) administered IV on day 4 following bortezomib (1.3 mg/m2 IV on days 1, 4, 8 and 11) or bortezomib alone every 3 weeks for up to 8 cycles or until disease progression or unacceptable toxicity. Patients who maintained a response were allowed to receive further treatment. The median number of cycles in each treatment arm was 5 (range 1-18).The baseline demographics and clinical characteristics of the patients with multiple myeloma were similar between treatment arms (Table 12).Table 12: Summary of Baseline Patient and Disease CharacteristicsPatient CharacteristicsDoxorubicin HCl liposome injection+ bortezomibn=324bortezomibn=322Median age in years (range)61 (28, 85)62 (34, 88)% Male/female58 / 4254 / 46% Caucasian/Black/other90 / 6 / 494 / 4 / 2Disease Characteristics% with IgG/IgA/Light chain57 / 27 / 1262 / 24 / 11% β2-microglobulin group ≤2.5 mg/L1414>2.5 mg/L and ≤5.5 mg/L5655>5.5 mg/L3031Serum M-protein (g/dL): Median (Range)2.5 (0-10.0)2.7 (0-10.0)Urine M-protein (mg/24 hours): Median (Range)107 (0-24883)66 (0-39657)Median Months Since Diagnosis35.237.5% Prior TherapyOne3434More than one6666Prior Systemic Therapies for Multiple MyelomaCorticosteroid (%)99>99Anthracyclines 68 67Alkylating agent (%) 92 90Thalidomide/lenalidomide (%)4043Stem cell transplantation (%) 57 54The primary outcome measure was time to progression (TTP). TTP was defined as the time from randomization to the first occurrence of progressive disease or death due to progressive disease. The combination arm demonstrated significant improvement in TTP. As the prespecified primary objective was achieved at the interim analysis, patients in the bortezomib monotherapy group were then allowed to receive the doxorubicin HCl liposome injection + bortezomib combination. Efficacy results are as shown in Table 13 and Figure 1.Table 13: Efficacy of Doxorubicin HCl Liposome Injection in Combination With Bortezomib in the Treatment of Patients With Multiple MyelomaEndpointDoxorubicin HCl liposome injection+ bortezomibn=324Bortezomibn=322Time to Progression1Progression or death due to progression (n)99150Censored (n)225172Median in days (months)282 (9.3)197 (6.5)95% CI250; 338170; 217Hazard ratio2(95% CI)0.55(0.43, 0.71)p-value3<0.001Response (n)4 303310% Complete Response (CR)53% Partial Response (PR)4340% CR + PR4843p-value50.25Median Duration of Response (months)10.27.0(95% CI)(10.2; 12.9)(5.9; 8.3)1Kaplan Meier estimate.2Hazard ratio based on stratified Cox proportional hazards regression. A hazard ratio < 1 indicates an advantage for doxorubicin HCl liposome injection +bortezomib.3Stratified log-rank test.4RR as per EBMT criteria.5Cochran-Mantel-Haenszel test adjusted for the stratification factors.Figure 1- Time to Progression Kaplan-Meier CurveAt the final analysis of survival, 78% of subjects in the doxorubicin HCl liposome injection and bortezomib combination therapy group and 80% of subjects in the bortezomib monotherapy group had died after a median follow up of 8.6 years. The median survival was 33 months in the doxorubicin HCl liposome injection and bortezomib combination therapy group and 31 months in the bortezomib monotherapy group. There was no difference observed in overall survival at the final analysis [HR for doxorubicin HCl liposome injection + bortezomib vs. bortezomib = 0.96 (95% CI 0.80, 1.14)]. Seventy-eight percent of subjects in the doxorubicin HCl liposome injection and bortezomib combination therapy group and 80% of subjects in the bortezomib monotherapy group had received subsequent therapy.

15 References

  • 1.“Hazardous Drugs”, OSHA, http://www.osha.gov/SLTC/hazardousdrugs/index.html

16 How Supplied/Storage And Handling

Doxorubicin HCl liposome injection is a sterile, translucent, red liposomal dispersion in 10-mL or 30-mL glass, single-dose vials.Each 10-mL vial contains 20 mg doxorubicin HCl at a concentration of 2 mg/mL.Each 30-mL vial contains 50 mg doxorubicin HCl at a concentration of 2 mg/mL.The following individually cartoned vials are available:Table 14mg in vialfill volumevial sizeNDC #s20 mg vial10-mL10-mL0338-0080-0150 mg vial25-mL30-mL0338-0086-01Refrigerate unopened vials of doxorubicin HCl liposome injection at 2°- 8°C (36°- 46°F). Do not freeze.Doxorubicin HCl liposome injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.1

17 Patient Counseling Information

CardiomyopathyAdvise patients to contact their healthcare provider if they develop symptoms of heart failure [see Warnings and Precautions (5.1)].Infusion-Related ReactionsAdvise patients about the symptoms of infusion related reactions and to seek immediate medical attention if they develop any of these symptoms [see Warnings and Precautions (5.2)].MyelosuppressionAdvise patients to contact their healthcare provider for a new onset fever or symptoms of infection.Hand-Foot SyndromeAdvise patients to notify their healthcare provider if they experience tingling or burning, redness, flaking, bothersome swelling, small blisters, or small sores on the palms of their hands or soles of their feet (symptoms of Hand-Foot Syndrome) [see Warnings and Precautions (5.3)].StomatitisAdvise patients to notify their healthcare provider if they develop painful redness, swelling, or sores in the mouth (symptoms of stomatitis).Embryofetal ToxicityAdvise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions (5.5) and Use in Specific Populations (8.1)].Advise females and males of reproductive potential to use effective contraception during and for 6 months following treatment with doxorubicin HCl liposome injection [see Use in Specific Populations (8.3)].LactationAdvise females not to breastfeed during treatment with doxorubicin HCl liposome injection [see Use in Specific Populations (8.2)].InfertilityAdvise females and males of reproductive potential that doxorubicin HCl liposome injection may cause temporary or permanent infertility [see Use in Specific Populations (8.3)].Discoloration of Urine and Body FluidsInform patients that following doxorubicin HCl liposome injection administration, a reddish-orange color to the urine and other body fluids may be observed. This nontoxic reaction is due to the color of the product and will dissipate as the drug is eliminated from the body.Manufactured for:Baxter Healthcare CorporationDeerfield, IL 60015 USA Baxter and Stealth are registered trademarks of Baxter International Inc. HA-30-01-873

* Please review the disclaimer below.